Back to Search
Start Over
Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain.
- Source :
-
Current Oncology . Dec2022, Vol. 29 Issue 12, p9891-9895. 5p. - Publication Year :
- 2022
-
Abstract
- The addition of pertuzumab to neoadjuvant trastuzumab and chemotherapy for women with early-stage, high-risk, HER2+ breast cancer has been observed to lead to higher pathologic complete response rates (pCR), and improved event-free survival compared to trastuzumab and chemotherapy alone. Based on available data, neoadjuvant pertuzumab is recommended by ESMO, ASCO, and NICE as well as by a Canadian Consensus Guideline Group. We discuss the implications for Canadian patients with HER2+ early breast cancer due to a second and final negative funding decision by the Canadian Agency for Drugs and Technologies in Health (CADTH) related to neoadjuvant pertuzumab. This decision will have adverse impacts for up to 1 in 6 women receiving neoadjuvant therapy for high-risk HER2+ breast cancer, due to suboptimal pCR rates and higher risks of invasive breast cancer recurrent events, resulting in the need for more toxic adjuvant therapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 11980052
- Volume :
- 29
- Issue :
- 12
- Database :
- Academic Search Index
- Journal :
- Current Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 160977681
- Full Text :
- https://doi.org/10.3390/curroncol29120778